Cargando…
Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy
Coronavirus disease 2019 (COVID-19) infection evokes severe proinflammatory storm and pulmonary infection with the number of confirmed cases (more than 200 million) and mortality (5 million) continue to surge globally. A number of vaccines (e.g., Moderna, Pfizer, Johnson/Janssen and AstraZeneca vacc...
Autores principales: | Li, Yiran E., Ajoolabady, Amir, Dhanasekaran, Muralikrishnan, Ren, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242686/ https://www.ncbi.nlm.nih.gov/pubmed/35779816 http://dx.doi.org/10.1016/j.phrs.2022.106334 |
Ejemplares similares
-
COVID-19-induced cardiovascular damage differs from other prevalent viruses
por: Parise, Rachel S., et al.
Publicado: (2021) -
COVID-19 isolation strategies: What have we learned
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022) -
What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021) -
Phage Therapy: What Have We Learned?
por: Górski, Andrzej, et al.
Publicado: (2018) -
Editorial: Immunomodulation of MSCs in tissue repairing and regeneration
por: Peng, Yanwen, et al.
Publicado: (2023)